Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 9:40 PM
Ignite Modification Date:
2025-12-24 @ 9:40 PM
NCT ID:
NCT03525132
Eligibility Criteria:
Inclusion Criteria:
* Willing and able to give written Informed Consent and to comply with the requirements of the study protocol
* Person affiliated to social security
* Age between 18 and 80 years
* Capable of focusing a target without ocular micro stuttering
* For healthy subject : absence of ocular and systemic pathology and no medical treatment
* For subject with glaucoma : Primitive open-angle glaucoma unilateral or bilateral. Visual field must be considerate as compatible and reliable with campimetric impairment known in glaucoma.
* For subject wih retinal veinous occlusion : Retinal central vein occlusion or branch retinal vein occlusion medically confirmed with an eye fundus exam and fluorescein angiography.
Non-inclusion Criteria:
* Subject mentioned in L1121-5 to L1121-8 article of French Health Code : pregnant women, women capable of child bearing without contraceptive measures, under-age subject, subject under juridic protection or not able to give informed consent, subject deprived of liberty
* Any systemic medication with action on intraocular pressure such as sympathomimetic and beta blocker
* Hypersensitivity to tropicamide or its derivatives or to any eye drops excipients
* Subject who do not want to take part to the study
* Subject participating to another clinical trial
* Subject who can't come back for follow up visits
* Subject with lenses and who can't stop wearing them for the study protocol
* Close or narrow anterior chamber angle
* For healthy subject : Ametropia \> 3 diopter, subject with non evolutive or evolutive ocular pathology
* For subject with glaucoma : Ametropia \> 3 diopter, secondary glaucoma, closed angle glaucoma, isolated intraocular hypertonia, eye surgery within 3 months before the beginning of the study, trabeculoplasty, filtration surgery, associated evolutive or non-evolutive ocular pathology
* For subject with retinal veinous occlusion : Ametropia \> 3, associated evolutive or non-evolutive ocular pathology, patient already treated with intravitreal injection with anti-VEGF or dexamethasone implant (no older than 4 months)
Healthy Volunteers:
True
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
80 Years
Study:
NCT03525132
Study Brief:
Protocol Section:
NCT03525132